Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy

Bambusa is advancing bispecifics in-licensed from Biotheus that bind pairs of targets separately validated in inflammatory and immunology indications to treat a wider range of symptoms. Its molecules have an extended half-life and are formulated for subcutaneous delivery. 

In May of last year, six months before Biotheus Inc. was acquired by Biontech SE (NASDAQ:BNTX) in an $800 million deal, Shanshan Xu, who was VP of external innovation at Biontech at the time, took over four of Biotheus’ candidates, now named BBT001-004, to start GLP tox at a new company: Bambusa Therapeutics Inc. ...